

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Hester Larkin
Date of Last Notice:	18 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>550,000</td><td>2,175,002</td></tr><tr><td>Indirect</td><td>94,247</td><td>-</td></tr><tr><td>Total</td><td>644,247</td><td>2,175,002</td></tr></table>				Shares	Options	Direct	550,000	2,175,002	Indirect	94,247	-	Total	644,247	2,175,002
	Shares	Options													
Direct	550,000	2,175,002													
Indirect	94,247	-													
Total	644,247	2,175,002													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>8,000,000</td></tr></table>				Shares	Options	Direct	-	8,000,000	Indirect	-	-	Total	-	8,000,000
	Shares	Options													
Direct	-	8,000,000													
Indirect	-	-													
Total	-	8,000,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash options issued, per resolution 12 approved by shareholders at the Annual General Meeting held on 25 November 2024		
No. of securities held after change		Shares	Options
	Direct	550,000	10,175,002
	Indirect	94,247	-
	Total	644,247	10,175,002
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolution 12 approved by shareholders at the Annual General Meeting held on 25 November 2024		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	23 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>2,530,595</td><td>6,127,524</td></tr><tr><td>Indirect</td><td>2,424,697</td><td>820,422</td></tr><tr><td>Total</td><td>4,955,292</td><td>6,947,946</td></tr></table>				Shares	Options	Direct	2,530,595	6,127,524	Indirect	2,424,697	820,422	Total	4,955,292	6,947,946
	Shares	Options													
Direct	2,530,595	6,127,524													
Indirect	2,424,697	820,422													
Total	4,955,292	6,947,946													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>A) 4,040,404 B) 8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>12,040,404</td></tr></table>				Shares	Options	Direct	-	A) 4,040,404 B) 8,000,000	Indirect	-	-	Total	-	12,040,404
	Shares	Options													
Direct	-	A) 4,040,404 B) 8,000,000													
Indirect	-	-													
Total	-	12,040,404													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A) Non-cash options issued, per resolution 8 approved by shareholders at the Annual General Meeting held on 25 November 2024 B) Non-cash options issued, per resolution 9 approved by shareholders at the Annual General Meeting held on 25 November 2024												
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>2,530,595</td><td>18,167,928</td></tr><tr><td>Indirect</td><td>2,424,697</td><td>820,422</td></tr><tr><td>Total</td><td>4,955,292</td><td>18,988,350</td></tr></table>		Shares	Options	Direct	2,530,595	18,167,928	Indirect	2,424,697	820,422	Total	4,955,292	18,988,350
	Shares	Options											
Direct	2,530,595	18,167,928											
Indirect	2,424,697	820,422											
Total	4,955,292	18,988,350											
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolutions 8 & 9 approved by shareholders at the Annual General Meeting held on 25 November 2024												

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Leila Alland
Date of Last Notice:	18 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>1,071,740</td><td>2,400,002</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>1,071,740</td><td>2,400,002</td></tr></table>				Shares	Options	Direct	1,071,740	2,400,002	Indirect	-	-	Total	1,071,740	2,400,002
	Shares	Options													
Direct	1,071,740	2,400,002													
Indirect	-	-													
Total	1,071,740	2,400,002													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>8,000,000</td></tr></table>				Shares	Options	Direct	-	8,000,000	Indirect	-	-	Total	-	8,000,000
	Shares	Options													
Direct	-	8,000,000													
Indirect	-	-													
Total	-	8,000,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash options issued, per resolution 13 approved by shareholders at the Annual General Meeting held on 25 November 2024														
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>1,071,740</td><td>10,400,002</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>1,071,740</td><td>10,400,002</td></tr></table>				Shares	Options	Direct	1,071,740	10,400,002	Indirect	-	-	Total	1,071,740	10,400,002
	Shares	Options													
Direct	1,071,740	10,400,002													
Indirect	-	-													
Total	1,071,740	10,400,002													
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolution 13 approved by shareholders at the Annual General Meeting held on 25 November 2024														

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Noel Donnelly
Date of Last Notice:	3 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>8,000,000</td></tr></table>				Shares	Options	Direct	-	8,000,000	Indirect	-	-	Total	-	8,000,000
	Shares	Options													
Direct	-	8,000,000													
Indirect	-	-													
Total	-	8,000,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash options issued, per resolution 10 approved by shareholders at the Annual General Meeting held on 25 November 2024		
No. of securities held after change		Shares	Options
	Direct	-	8,000,000
	Indirect	-	-
	Total	-	8,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolution 10 approved by shareholders at the Annual General Meeting held on 25 November 2024		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Phillip Hains
Date of Last Notice:	18 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>15,956,632</td><td>6,933,560</td></tr><tr><td>Total</td><td>15,956,632</td><td>8,833,562</td></tr></table>				Shares	Options	Direct	-	1,900,002	Indirect	15,956,632	6,933,560	Total	15,956,632	8,833,562
	Shares	Options													
Direct	-	1,900,002													
Indirect	15,956,632	6,933,560													
Total	15,956,632	8,833,562													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>8,000,000</td></tr></table>				Shares	Options	Direct	-	8,000,000	Indirect	-	-	Total	-	8,000,000
	Shares	Options													
Direct	-	8,000,000													
Indirect	-	-													
Total	-	8,000,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash options issued, per resolution 11 approved by shareholders at the Annual General Meeting held on 25 November 2024		
No. of securities held after change		Shares	Options
	Direct	-	9,900,002
	Indirect	15,956,632	6,933,560
	Total	15,956,632	16,833,562
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolution 11 approved by shareholders at the Annual General Meeting held on 25 November 2024		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	10 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>53,900,000</td><td>27,500,000</td></tr><tr><td>Indirect</td><td>93,821,428</td><td>9,017,518</td></tr><tr><td>Total</td><td>147,721,428</td><td>36,517,518</td></tr></table>				Shares	Options	Direct	53,900,000	27,500,000	Indirect	93,821,428	9,017,518	Total	147,721,428	36,517,518
	Shares	Options													
Direct	53,900,000	27,500,000													
Indirect	93,821,428	9,017,518													
Total	147,721,428	36,517,518													
Class	Unlisted options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>8,000,000</td></tr></table>				Shares	Options	Direct	-	8,000,000	Indirect	-	-	Total	-	8,000,000
	Shares	Options													
Direct	-	8,000,000													
Indirect	-	-													
Total	-	8,000,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash options issued, per resolution 6 approved by shareholders at the Annual General Meeting held on 25 November 2024		
No. of securities held after change		Shares	Options
	Direct	53,900,000	35,500,000
	Indirect	93,821,428	9,017,518
	Total	147,721,428	44,517,518
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Per resolution 6 approved by shareholders at the Annual General Meeting held on 25 November 2024		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	18 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.															
Date of change	12 December 2024 – 16 December 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>12,253,584</td><td>55,699,013</td></tr><tr><td>Indirect</td><td>1,150,000</td><td>-</td></tr><tr><td>Total</td><td>13,403,584</td><td>55,699,013</td></tr></table>				Shares	Options	Direct	12,253,584	55,699,013	Indirect	1,150,000	-	Total	13,403,584	55,699,013
	Shares	Options													
Direct	12,253,584	55,699,013													
Indirect	1,150,000	-													
Total	13,403,584	55,699,013													
Class	RAD Ordinary Fully Paid Shares Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>7,776,402</td><td>55,250,286</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>7,776,402</td><td>55,250,286</td></tr></table>				Shares	Options	Direct	7,776,402	55,250,286	Indirect	-	-	Total	7,776,402	55,250,286
	Shares	Options													
Direct	7,776,402	55,250,286													
Indirect	-	-													
Total	7,776,402	55,250,286													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td></td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td></td><td>-</td></tr></table>				Shares	Options	Direct		-	Indirect	-	-	Total		-
	Shares	Options													
Direct		-													
Indirect	-	-													
Total		-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<div>1) 684,787 shares purchased at \$0.028 and \$0.029 per share.</div> <div>2) \$0.031 per share.</div> <div>3) Non-cash options issued, per resolution 7 approved by shareholders at the Annual General Meeting held on 25 November 2024</div>												
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>20,029,986</td><td>110,949,299</td></tr><tr><td>Indirect</td><td>1,150,000</td><td>-</td></tr><tr><td>Total</td><td>21,179,986</td><td>110,949,299</td></tr></table>		Shares	Options	Direct	20,029,986	110,949,299	Indirect	1,150,000	-	Total	21,179,986	110,949,299
	Shares	Options											
Direct	20,029,986	110,949,299											
Indirect	1,150,000	-											
Total	21,179,986	110,949,299											
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<div>1) On-market trades</div> <div>2) Issuance of shares per pre-employment contract.</div> <div>3) Issuance of options per resolution 7 approved by shareholders at the Annual General Meeting held on 25 November 2024.</div>												

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.